CVMP opinions on veterinary medicinal products

The Committee adopted a positive opinion on a marketing authorisation from Elanco for Lotilaner / Milbemycin Elanco (lotilaner / milbemycin oxime), for use in dogs with, or at risk from, mixed infestations/infections by ticks, fleas, mites, gastrointestinal nematodes, heartworm and/or lungworm.

The Committee adopted by consensus positive opinions for variations concerning quality-related changes for:

• Arti-Cell Forte
• Improvac and NAPs (WS) (worksharing procedure)
• Librela / Equip WNV / Suvaxyn CSF Marker / Suvaxyn Circo+MH RTU / Cytopoint / Suvaxyn Circo / Suvaxyn PRRS MLV / CircoMax / CircoMax Myco/Solensia and NAPs (worksharing procedure)
• Purevax RCPCh  / Purevax RCPCh FeLV (worksharing procedure)
• Strangvac
• Vectormune ND/Vectormune HVT-AIV/Newflend ND H9/Ultifend ND IBD (worksharing procedure)
• Versican Plus DHPPi/L4R / Versican Plus DHPPi/L4 / Versican Plus DHPPi / Versican Plus Pi / Versican Plus Pi/L4R / Versican Plus…